Celgene Shares Fall as Sales of Key Cancer Drug Disappoint

Celgene said quarterly earnings more than tripled but sales of its most important product, cancer drug Revlimid, were smaller than expected.

Net income rose to $57.4 million, or 14 cents a share, from $16 million, or 4 cents a share, a year ago.

Excluding one-time items, the company earned 20 cents a share. Analysts had on average expected earnings of 20 cents a share, according to Thomson Financial.

Revenue rose 61.4 percent to $293.4 million, driven by sales of Revlimid, which came in at $146.2 million. Analysts, however, had on average expected Revlimid sales of $150 million, according to a report by Leerink Swann & Co.

The company reiterated its outlook for 2007 of earnings of $1.00 a share on revenue of about $1.3 billion. Analysts on average expect earnings of $1.04 a share.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Charles Rotblut, American Association of Individual Investors, reveals the results on an AAII survey which shows positive investment sentiment rose slightly. Most of our members take a long-term outlook, says Rotblut.

  • CNBC's Josh Lipton talks with Apple's Eddy Cue about what consumers can expect to see in Apple's latest product - Apple Pay.

  • Michael Pearson, Valeant Pharmaceuticals CEO, shares his thoughts on allegations Allergan released false and misleading information.